The molecular mechanisms whereby CD8 + T cells become ''exhausted'' in the tumor microenvironment remain unclear. Programmed death ligand-1 (PD-L1) is upregulated on tumor cells and PD-1-PD-L1 blockade has significant efficacy in human tumors; however, most patients do not respond, suggesting additional mechanisms underlying T cell exhaustion. B7 superfamily member 1 (B7S1), also called B7-H4, B7x, or VTCN1, negatively regulates T cell activation. Here we show increased B7S1 expression on myeloid cells from human hepatocellular carcinoma correlated with CD8 + T cell dysfunction. B7S1 inhibition suppressed development of murine tumors. Putative B7S1 receptor was co-expressed with PD-1 but not T cell immunoglobulin and mucin-domain containing-3 (Tim-3) at an activated state of early tumor-infiltrating CD8 + T cells, and B7S1 promoted T cell exhaustion, possibly through Eomes overexpression. Combinatorial blockade of B7S1 and PD-1 synergistically enhanced anti-tumor immune responses. Collectively, B7S1 initiates dysfunction of tumor-infiltrating CD8 + T cells and may be targeted for cancer immunotherapy.
In Brief
Mechanisms driving T cell exhaustion have not been understood. Li et al. demonstrate that B7S1 on tumorinfiltrating myeloid cells initiates exhaustion of activated CD8 + TILs through upregulating Eomes, thus proposing B7S1 as a promising target to enhance the efficacy of anti-PD-1 therapy.
SUMMARY
The molecular mechanisms whereby CD8 + T cells become ''exhausted'' in the tumor microenvironment remain unclear. Programmed death ligand-1 (PD-L1) is upregulated on tumor cells and PD-1-PD-L1 blockade has significant efficacy in human tumors; however, most patients do not respond, suggesting additional mechanisms underlying T cell exhaustion. B7 superfamily member 1 (B7S1), also called B7-H4, B7x, or VTCN1, negatively regulates T cell activation. Here we show increased B7S1 expression on myeloid cells from human hepatocellular carcinoma correlated with CD8 + T cell dysfunction. B7S1 inhibition suppressed development of murine tumors. Putative B7S1 receptor was co-expressed with PD-1 but not T cell immunoglobulin and mucin-domain containing-3 (Tim-3) at an activated state of early tumor-infiltrating CD8 + T cells, and B7S1 promoted T cell exhaustion, possibly through Eomes overexpression. Combinatorial blockade of B7S1 and PD-1 synergistically enhanced anti-tumor immune responses. Collectively, B7S1 initiates dysfunction of tumor-infiltrating CD8 + T cells and may be targeted for cancer immunotherapy.
INTRODUCTION
Although the immune system, especially tumor-specific CD8 + T cells, can function to inhibit tumor growth, CD8 + T cells often become dysfunctional, or ''exhausted,'' in the tumor microenvironment (TME). T cell exhaustion, first identified in chronic lymphocytic choriomeningitis virus (LCMV) infection model, is accompanied by gradual loss of effector function and proliferation potential which hinder virus clearance by CD8 + T cells, underscored by altered transcriptional and epigenetic programs and increased expression of inhibitory checkpoint receptors (Blackburn et al., 2009; Wherry, 2011; Wherry et al., 2007) . Exhausted T cells upregulate the expression of co-inhibitory receptor PD-1, while blockade of PD-1 interaction with its ligand PD-L1 reinvigorates exhausted CD8 + T cells during chronic LCMV infection (Wherry and Kurachi, 2015) . Exhaustion of CD8 + T cells is also found in tumors and overexpression of PD-L1 on tumor cells is sufficient to inhibit cytotoxicity of CD8 + T cells (Juneja et al., 2017) . Blockade of PD-1-PD-L1 pathway can rejuvenate CD8 + T cells in tumor and has been approved for treatment of advanced melanoma, non-small cell lung cancer, head and neck cancer, and kidney cancer (Schildberg et al., 2016) . However, despite pre-existing PD-1 + exhausted CD8 + T cells in the tumor of hepatocellular carcinoma (HCC), an inflammation-associated cancer, the overall response rate of HCC patients to anti-PD-1 therapy is only 20% (El-Khoueiry et al., 2017) . In many other types of cancer, only a small population ($30%) responds to anti-PD-1 or anti-PD-L1 therapy while the non-responders undergo transient reinvigoration of exhausted T cells followed by disease relapse (Huang et al., 2017; Ribas et al., 2016) , perhaps because exhausted T cells acquire an inflexible epigenetic fate distinct from that of effector or memory T cells that is minimally remodeled by blockade of PD-1 pathway (Pauken et al., 2016; Sen et al., 2016) , suggesting additional mechanisms driving T cell exhaustion. Since the immune checkpoint molecules function non-redundantly and cooperatively to fine-tune immune responses and promote T cell exhaustion (Li et al., 2017) , additional immunosuppressive mechanisms need to be identified and possible combinatorial treatment should be tested in order to reverse T cell exhaustion and improve the efficacy of cancer immunotherapy. B7S1 (B7-H4, B7x, VTCN1), one of the members in B7 family, was identified in 2003 (Prasad et al., 2003; Sica et al., 2003) , sharing 18% and 24% amino acid identity with human PD-L1 and B7-H3, respectively (Zang et al., 2003) . It consists of two D56 56 5  D56 6  56  D 6 6 6  56   CD3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3   CD3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 CD8 T immunoglobulin (Ig)-like domains and a large hydrophobic transmembrane domain followed by two intracellular amino acids. B7S1 protein expression is restricted to professional antigenpresenting cells (APCs) and can be induced by interleukin-10 (IL-10) and IL-6 (Kryczek et al., 2006 (Kryczek et al., , 2007 . Its putative receptor is induced on activated T cells to suppress their proliferation, cytokine production, and cytotoxicity (Prasad et al., 2003; Sica et al., 2003) . Since expression of B7S1 is found in multiple solid tumors and negatively correlates with patient outcome and infiltration of T cells in the tumor (Chen et al., 2011 (Chen et al., , 2012 Jiang et al., 2010; Kryczek et al., 2007; Quandt et al., 2011; Xu et al., 2016; Zang et al., 2007) , B7S1 may serve as a promising candidate target for cancer immunotherapy to reinvigorate anti-tumor T cell function. However, the functional significance of B7S1 in tumor immunity and the molecular mechanisms whereby B7S1 inhibits T cell function have not been established. Moreover, the receptor of B7S1 has not been identified so far and its expression pattern in the tumor has not been established.
In this study, we found the expression of B7S1 in HCC correlated with T cell dysfunction. B7S1 inhibition suppressed the development of mouse tumor models. Putative B7S1 receptor was expressed at an activated state of early tumor-infiltrating CD8 + T cells, and B7S1 promoted T cell exhaustion via upregulating Eomes. Our results have offered important insights into the molecular pathways that mediate T cell exhaustion and supported B7S1 as a promising target for immunotherapy.
RESULTS

B7S1 Inhibition Suppresses the Development of Liver Cancer
To determine whether B7S1 can be a potential target for cancer immunotherapy, we first assessed the expression of B7S1 in the blood and freshly isolated tumor tissues from patients with hepatocellular carcinoma (HCC). Myeloid DCs (mDCs), plasmacytoid DCs (pDCs), CD14 + HLA-DR hi cells, and CD14 + HLA-DR lo/À cells from the peripheral blood of HCC patients expressed higher amounts of B7S1 compared with the counterparts from healthy donors ( Figure S1A ). Moreover, serum from HCC patients promoted B7S1 expression on antigen-presenting cells (APCs) from healthy donors (data not shown), suggesting that tumor carriage might upregulate the expression of B7S1 on APCs, which might serve as a biomarker for this cancer. We next compared the expression of B7S1 on APCs isolated from PBMC, normal liver, para-tumor, and tumor of HCC patients by flow cytometry. Within the liver tissues in HCC patients, B7S1-expressing mDCs and CD14 + HLA-DR hi cells were also increased in percentages than those in the circulation ( Figures 1A and 1B Figure S1C ). We also measured the expression of B7S1 in the resected tissues and tumor by immunofluorescence since the CD45 À portion might be lost during the isolation of tissue-infiltrating cells for flow cytometric analysis. Most of B7S1 expression was observed on CD45 + cells and higher B7S1 expression was found in para-tumor and tumor tissues ( Figure 1C ). B7S1 expression in the tumor did not correlate with hepatitis B virus positivity, though (data not shown). In contrast, PD-L1 was mainly expressed on CD45 À cells but not on professional APCs in HCC patients, while its expression was similar among normal liver, para-tumor, and tumor ( Figures  S1D and S1E ). B7S1 was reported to bind to activated T cells and inhibit their proliferation and function (Prasad et al., 2003; Sica et al., 2003) . We thus utilized a biotin-labeled human B7S1-mouse IgG2a Fc fusion protein to measure the expression of the putative receptor for B7S1. CD8 + T, CD4 + T, and NK cells from the blood of HCC patients displayed higher expression of B7S1 receptor (B7S1R) than their counterparts in healthy donors ( Figure S1B ). Expression of B7S1R was higher on CD8 + T, CD4 + T, and NKT cells in the liver tissues than in the peripheral ( Figures 1D and 1E ). Moreover, frequency of Granzyme B + Perforin + CD8 + tumor-infiltrating lymphocytes (TILs) negatively correlated with B7S1 but not PD-L1 expression in the tumor regardless of HBV status ( Figures  1C and S1E ), suggesting that B7S1 expression in the TME may inhibit CD8 + T cell function.
The above human HCC data suggested that B7S1 and its receptor were expressed in the liver and might inhibit anti-tumor immune responses in HCC patients. In order to study the functional role of B7S1 in liver cancer, we took advantage of a transplantable mouse HCC model: Hepa1-6. First, we examined the expression patterns of B7S1 and its receptor in this murine model. B7S1 was highly expressed on CD11b + , F4/80 + , and CD11c + APCs but not on CD45 À cells in the tumor, while moderate expression was seen on CD3 + T cells ( Figure S2A ). Expression of B7S1R was evaluated by a biotinylated mouse B7S1-human IgG1 Fc fusion protein. In the tumor tissues, B7S1R was mainly expressed on CD8 + T cells ( Figure S2B ). Next, we determined whether deficiency or blockade of B7S1 affected the tumor progression in this model. Logarithmically growing Hepa1-6 was injected subcutaneously into wild-type (WT) and Vtcn1 À/À (B7S1 knockout) mice, and tumor growth was monitored daily for 23 days. Deficiency of B7S1 significantly inhibited the growth of Hepa1-6 tumor ( Figure 2A ). We also tested the therapeutic effects of B7S1 blockade in this model using an anti-B7S1 blockade antibody (clone 54) (Prasad et Figure S1 . (F) Expression of B7S1 receptor on tumor-infiltrating lymphocytes from E.G7-bearing mice (day 21).
(G) Expression of B7S1 receptor on total and OVA-specific CD8 + T cells in the tumor-draining lymph nodes (TDLN) and tumor from E.G7-bearing mice (n = 4).
(legend continued on next page) 2003). 100 mg of control antibody or anti-B7S1 antibody was injected intraperitoneally into WT mice every other day starting from day 5 after tumor inoculation. As expected, mice treated with anti-B7S1 antibody showed slower tumor growth of Hepa1-6 than those treated with the control antibody ( Figure 2A) . Thus, our results indicate that B7S1 inhibits anti-tumor immune responses in HCC, probably through suppressing the function of CD8 + T cells.
B7S1 Inhibition Suppresses Growth of Hematopoietic Tumors
Having demonstrated the tumor-promoting effects of B7S1 in the non-hematopoietic tumor model Hepa1-6, we next sought to explore the role of B7S1 in hematopoietic cancer and investigate the underlying mechanism. As expected, blockade of B7S1 increased the survival of mice intravenously inoculated with A20, a mouse B cell lymphoma ( Figure 2B ). In addition, the effects of B7S1 inhibition were also tested in mice subcutaneously inoculated with 10 6 E.G7, a mouse T cell lymphoma derived from EL4.
Lack of B7S1 or blockade of B7S1 by clone 54 (starting from day 5) inhibited subcutaneous tumor growth of E.G7 ( Figure 2C ). B7S1 blockade significantly suppressed development of E.G7 tumor even when it was conducted in a therapeutic context, after tumor growth was initiated (starting from day 9, Figure S2C ). Moreover, anti-B7S1 antibody-treated E.G7-bearing mice showed stronger inhibition of tumor growth than the control group when re-challenged with transplanted tumor cells on the other site ( Figure 2D ), suggesting that anti-B7S1 blockade elicits a memory response against tumor. In order to study the immune mechanism by which B7S1 and its receptor suppress anti-tumor immunity more closely, we focused on the E.G7 model with chicken ovalbumin (OVA) protein expression by tumor cells, to allow the study of tumor antigen-specific immune responses. Unlike Hepa1-6 model, high expression of B7S1 was observed on both APCs and tumor cells in the E.G7 model ( Figure 2E ). Moderate B7S1 expression was observed on CD3 + T cells, among which CD8 + T cells exhibited the highest expression ( Figure S2D ). Immunofluorescence staining was performed on E.G7 tumor sections to detect expression of B7S1 in the tumor microenvironment. hi tumor-associated DCs (TADCs) using the gating strategy described previously (Laoui et al., 2014) . Ly6C + MHCII hi immature macrophages, MHCII hi TAMs, and especially TADCs displayed high expression of B7S1, higher than the counterparts in the spleen ( Figure S2F ). However, expression of B7S1R was not detected on myeloid cell subsets ( Figure S2G ) or tumor cells (data not shown). Consistent with Hepa1-6 tumor, CD8 + TIL was the major population expressing B7S1R in the E.G7 tumor ( Figure 2F ), which expressed higher amounts of B7S1R than those in the spleen and lymph nodes. However, in the peripheral, B7S1R was highly expressed on NK and gdT cells in the lymph nodes ( Figure S2H ). The B7S1R + CD8 + T cells were more enriched in the OVA-specific subpopulation than total CD8 + tumor-infiltrating T cells (Figure 2G) , indicating that B7S1R is upregulated on tumor-specific CD8 + T cells upon antigenic encounter.
Immunosuppression by B7S1 Involves Crosstalk between CD8 + T Cells and APCs
To identify the target cells of B7S1, we depleted CD8 + T, CD4 + T, or NK cells in E.G7-bearing WT and Vtcn1 À/À mice. Anti-tumor effects in Vtcn1 À/À mice were abrogated only when CD8 + T cells were depleted ( Figure 2H ). Since B7S1 was expressed on both APCs and tumor cells in the E.G7 model, we assessed whether B7S1 expression on APCs or tumors plays a more important role in mediating immunosuppression. We thus used anti-B7S1 blockade antibody in E.G7-bearing Vtcn1 À/À mice to block B7S1 on tumor cells when B7S1 on APCs was absent.
As a result, we did not observe further inhibition of tumor growth in Vtcn1 Next we sought to study the functional status of CD8 + TILs expressing B7S1R. First, we compared its expression with that of other co-inhibitory receptors. It is known that co-expression of PD-1 and Tim-3 marks T cell exhaustion. Expression of B7S1R seemed to correlate with infiltration or expansion of CD8 + T cells in the tumor: it appeared on day 6 when CD8 + T cells started to appear in the tumor, reached the peak on day 12, and then decreased to around 20% on day 21, while the expression of PD-1 and Tim-3 kept increasing or stayed high. Moreover, B7S1R was always co-expressed with PD-1 but not Tim-3 (Figure 3A) . The adoptively transferred naive OT-1 cells in the tumor also displayed the similar kinetics ( Figure S3A ), which indicates that B7S1R might be induced on early tumor-infiltrating CD8 + effector T cells before they become exhausted. Figure 3B ).
To better understand the functional status of B7S1R-expressing CD8 + T cells in the TME, the transcriptional profiles of different CD8 + TIL subpopulations were measured to investigate the molecular programs associated with the functional status. Here we identified 4,790 differentially expressed genes among these 3 subsets. PD-1 These experiments were repeated three times. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2 .
while PD-1 + B7S1R À Tim-3 + CD8 + TILs were distinct ( Figure 3C ).
Seven clusters (C1-C7) with distinct expression patterns were identified by k-means clustering ( Figure 3C and Figure 3D ; Wherry et al., 2007) . In addition, pathway (C) Heatmap of the 4,790 differentially expressed genes across the three PD-1 + CD8 + TIL subpopulations. See also Table S1 .
(D) Enrichment analysis for each cluster with gene signatures generated from the literature. p values are determined by hypergeometric test. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S3 and Table S1 . (legend continued on next page) analysis revealed that genes in C7 were enriched for negative regulation of T cell receptor signaling pathway (e.g., Cblb, Ubash3a), while C6 showed enrichment of regulation of T cell differentiation (e.g., Stat5a, Stat5b, Ikzf1) ( Figure S3B ). Nonetheless, most of these clusters were also enriched for genes induced by in vitro TCR stimulation (Table S1 ). Therefore, PD-1 + CD8 + TILs can be further categorized into different subsets with distinct functional spectrums based on expression of B7S1R and Tim-3: co-expression of B7S1R and PD-1 marks an activation status of CD8 + TILs, while co-expression of Tim-3 and PD-1 serves as a marker for T cell exhaustion.
B7S1 Inhibition Enhances Anti-tumor CTL
The above analysis suggests that B7S1 may signal in tumorspecific CD8 + T cells during their early entry into TME, likely in response to tumor antigens presented by tumor-resident APCs. To understand the mechanism of immunosuppression mediated by B7S1, we compared the phenotypic changes in E.G7-bearing Vtcn1 À/À versus WT mice. B7S1 deficiency did not alter the expression of CD80 and CD86 in tumor-infiltrating myeloid subsets ( Figures S4A and S4B ). However, we observed increased percentages of CD8 + T cells, as well as increased CD8/CD4 ratio and CD8/regulatory T (Treg) cell ratio, in the tumor of Vtcn1 À/À mice ( Figure S4C ). In addition, frequency of OVA-specific CD8 + T cells stained with SIINFEKL H2-K b pentamer was higher in the tumor-draining lymph nodes (TDLN) and tumor from Vtcn1 À/À mice compared with WT mice (Figure 4A ). In accordance with the increased numbers, both total CD8 + TILs and OVA-specific CD8 + TILs from Vtcn1 À/À mice exhibited increased expression of Ki67 ( Figure 4B ). Furthermore, CD8 + TILs, but not NK cells, from Vtcn1 À/À mice displayed higher baseline surface expression of CD107a, a degranulation marker, and produced more Granzyme B and IFN-g upon PMA and ionomycin stimulation in comparison with those from WT mice ( Figures 4C and S4D ). We also confirmed the cytolytic activity of the tumor-infiltrating effector cells using ex vivo cytolytic assay, in which we sorted CD8 + T cells and NK cells from spleen and tumor of WT and Vtcn1 À/À mice, cultured them with CFSElabeled E.G7 for 5 hr, and used the amount of intracellular cleaved caspase-3 in E.G7 as a readout of cytotoxicity of the effector cells. CD8 + T cells, but not NK cells, from the tumors of Vtcn1 À/À mice displayed enhanced cytolytic activity to target cells ( Figure 4D ). In the Hepa1-6 model, we also observed enhanced cytolytic activity (marked by increased surface CD107a expression at baseline and increased PMA&ionomycin-stimulated Granzyme B, Perforin, and IFN- Figure S5C ). In conclusion, our findings demonstrate that B7S1 on APCs promotes tumor development via suppressing expansion and cytotoxicity of CD8 + effector T cells in the TME.
B7S1 Promotes CD8 + T Cell Exhaustion via Eomes
In order to understand how B7S1 signaling contributes to dysfunction of CD8 + T cell in the TME, we conducted transcriptional analysis of OVA-specific CD8 + TILs from E.G7-bearing WT and Vtcn1 À/À mice (day 21). 1,013 genes were upregulated and 1,120 genes were downregulated in OVA-specific CD8 + TILs from Vtcn1 À/À mice compared to those from WT mice (p < 0.05, fold change R 2). Pathway analysis revealed more prominent changes in cell cycle pathway and NF-kB pathway (Table S2) . Genes involved in enter of cell cycle and cytolysis were upregulated in the KO group ( Figure 5A ), consistent with our previous findings that B7S1 inhibition enhanced proliferation and cytotoxicity of CD8 + TILs (Figure 4) . Besides, abrogation of B7S1 signaling led to upregulation of co-stimulatory ligands or receptors (e.g., Icosl, Cd27, Cd28). Moreover, B7S1 deficiency resulted in downregulation of some co-inhibitory receptors (e.g., Lag3, Ctla4) and upregulation of other co-inhibitory receptors (e.g., Lilrb4, Pdcd1) ( Figure 5A ). Gene set enrichment analysis (GSEA) revealed that the gene sets defined as upregulated in exhausted T cells in autochthonous melanoma (Giordano et al., 2015) and chronic LCMV infection (Wherry et al., 2007) were enriched in OVA-specific CD8 + TILs from WT mice, while those from Vtcn1 À/À mice exhibited characters for activated and effector T cells ( Figures 5B and 5C ). In addition, many effector genes were biased toward the Vtcn1 À/À group (Figure 5D) (Table S3 ).
Hierarchical clustering of DEGs was conducted to identify specific changes induced by B7S1 deficiency in each TIL subset ( Figure S5E (D) CD8 + T and NK cells were isolated from spleen and TILs from E.G7-bearing WT and Vtcn1 À/À mice (day 21, n = 5 per group) using FACS sorting. E.G7 was labeled with CFSE and pulsed with 3 mg/mL OVA257-264 (1 hr at 37 C). Then CD8 + T or NK were mixed with E.G7 at 1:1 ratio and incubated for 5 hr. Cells were fixed and permeabilized and stained with anti-cleaved caspase 3-PE (1:100). Representative figures and summary histograms of intracellular cleaved caspase 3 in E.G7, which indicates the ex vivo cytolytic activity of co-cultured effector cells. Data represent analyses of n mice per group, mean ± SEM. These experiments were repeated 3 times. *p < 0.05, **p < 0.01, ****p < 0. Of note, Eomesodermin (Eomes), a transcription factor whose expression was highly associated with T cell exhaustion (Wherry et al., 2007) , was significantly downregulated in OVA-specific CD8 + TILs from Vtcn1 À/À mice both transcriptionally and translationally ( Figures 5A and 5E ). Transcription factor (TF) motif analysis following ATAC-seq experiment on OVA-specific CD8 + TILs from mice treated with control versus anti-B7S1 antibodies also revealed loss of Eomes-binding motifs caused by anti-B7S1 treatment ( Figure 5F and Table S2 ). However, similar effect was not observed in CD8 + TILs when mice were treated with anti-PD-1 (data not shown), suggesting a unique regulation by B7S1 on Eomes. To examine the role of Eomes in regulating T cell exhaustion, we investigated the effects of Eomes overexpression in CD8 + T cells under chronic TCR stimulation in vitro. Eomes-overexpressing OT-I cells showed dampened production of IFN-g and TNF-a when re-stimulated with OVA peptide or anti-CD3 for 3 days. However, this effect was compromised in the presence of CD28 co-stimulation ( Figure 5G ). Moreover, in order to investigate whether Eomes is directly involved in B7S1:B7S1R co-inhibitory pathway, we overexpressed Eomes in OT-I cells and found it abrogated the enhancement of their in vivo cytotoxicity by anti-B7S1 blockade ( Figure 5H ). Thus, B7S1 and its receptor might promote T cell exhaustion in the TME via upregulation of Eomes.
Combination of B7S1 and PD-1 Blockade Synergistically Inhibits Tumor Growth
Since the ligand of PD-1, PD-L1, also exists in the tumor of Hepa1-6 and E.G7 (data not shown), PD-1 is upregulated on CD8 + TILs when B7S1 is inhibited ( Figure S6A ) and CD8 + TILs co-express B7S1R and PD-1 ( Figure 3A) , we hypothesized that combinational blockade of B7S1 and PD-1 pathways can inhibit tumor growth more potently than monotherapies. WT mice were subcutaneously inoculated with E.G7 or Hepa1-6 and treated with control, anti-B7S1, anti-PD-1, or anti-B7S1 plus anti-PD-1 antibodies on day 9, 12, 15, and 18 via intraperitoneal injection. Although either anti-B7S1 or anti-PD-1 monotherapy exhibited moderate anti-tumor effects, combination of B7S1 and PD-1 blockade showed synergic effects on inhibition of tumor growth in both E.G7 and Hepa1-6 model, further reducing the tumor to a very small volume ( Figures 6A and S6B) . In order to further understand the mechanisms whereby blockade of B7S1 or PD-1 inhibits tumor growth, we conducted ATAC-seq and RNA-seq analysis of OVA-specific CD8 + TILs from E.G7-bearing mice treated with control antibodies, anti-B7S1, anti-PD-1 monotherapy, or combinational therapy. We first compared whether B7S1 and PD-1 blockade impacted distinct downstream pathways. Largely overlapping epigenetic and transcriptional changes (>50%) were induced by anti-B7S1 and anti-PD-1 treatment ( Figure 6B ). Of the top 30 pathways regulated by each treatment, 17 were shared (e.g., cell cycle, mTOR signaling pathway, TCR signaling pathway), indicating that large part of T cell dysfunction is co-regulated by B7S1 and PD-1, suggesting that checkpoint molecules may exert their function via similar pathways. There were also some pathways specifically controlled by each one of them. FoxO signaling pathway and TNF signaling pathway were among the pathways most significantly modulated only by anti-PD-1, while anti-B7S1 selectively induced changes in metabolic pathways, e.g., glycolysis (Figures  6C and S6C and Table S4 ). Therefore, B7S1R and PD-1, through expressed by the same cell in the tumor, might suppress antitumor CD8 + T cells coordinately and might act via the shared downstream components, which may underscore the low response rates in patients treated with PD-1 blockade. Next, we investigated whether combinational therapy induces new changes that were not found in monotherapies. By comparing the open chromatin regions (OCRs) and differentially expressed genes (DEGs) of each treatment with control, we identified unique epigenetic and transcriptional changes induced by combinational therapy ( Figure 6D , Table S4 ). The ATAC-seq tracks were aligned with the previously reported OCRs of exhausted, effector, memory, and naive CD8 + T cells from chronic LCMV infection (Pauken et al., 2016) . In addition to peaks identified in chronic LCMV infection previously, there were new peaks that came up in our dataset, suggesting differences between tumor and chronic viral infection in epigenetic reprogramming of T cell exhaustion. Combinational therapy (B) Gene set enrichment of genes describing for exhausted CD8 + T cells in mouse autochthonous melanoma, relative to activated CD8 + T cells in acute infection (Giordano et al., 2015) .
(C) GSEA of exhaustion signatures in chronic viral infection (Doering et al., 2012) .
(D) GSEA of effector genes (Pauken et al., 2016) . Genes from the left to right of the rank-ordered list are enriched in Vtcn1 À/À and WT group, respectively.
(E) Expression of Eomes in OVA-specific CD8 + TILs from WT and Vtcn1 À/À mice detected by flow cytometry.
(F) Enrichment of TF binding motifs in OCRs of OVA-specific CD8 + TILs gained or lost after anti-B7S1 treatment.
(G) Production of IFN-g and TNF-a by hCD2 + OT-I cells with or without Eomes overexpression when re-stimulated with 250 ng/mL OVA peptide, 2.5 ng/mL OVA peptide, anti-CD3, or anti-CD3+CD28 for 3 days.
(H) Tumor volume of E.G7-bearing mice (n = 6 per group) adoptively transferred with control hCD2 + OT-I or hCD2 + OT-I overexpressing Eomes on day 14 combined with Rat IgG or anti-B7S1 treatment (i.p. on day 14, 16, 18). These experiments were repeated three times. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S5 and Tables S2 and S3 . Data represent analyses of 6 mice per group, mean ± SEM. These experiments were repeated twice. *p < 0.05, **p < 0.01.
(legend continued on next page)
induced loss of peaks in loci enriched in exhausted T (Tex) cells (e.g., Ctla4 locus) and gain of peaks in some loci enriched in effector T (Teff) cells (e.g., Il12rb2, Gzmb, Lamp1 locus). Some other Tex cell-specific peaks (e.g., Il10, Tox locus) were lost and Teff cell-specific peaks (e.g., Prf1 locus) were gained in both monotherapies and combinational therapy ( Figures 6E  and S6D ). Moreover, GSEA revealed that effector-associated genes were most enriched in combinational treatment (Figure 6F ). Upregulation of some effector genes (e.g., Lamp1, Lyz2, and Tnf) and downregulation of some exhaustion-associated genes (e.g., Cd160 and Cd200) was specifically induced by combinational therapy ( Figure 6G ). In addition, we classified DEGs of the 4 different treatments into 12 clusters and conducted pathway analysis ( Figures S6E and 6H and Table S5 ). Cluster 2, which contained genes upregulated only by combinational therapy, was enriched in positive regulation of tyrosine phosphorylation of Stat5, cell cycle, cellular response to IL-6, and negative regulation of apoptosis pathways. Genes in cluster 9, which was down only in combinational therapy, were enriched in apoptosis-associated pathways. Cluster 7, which was increased in anti-PD-1 or combo group, was enriched for cell cycle, cytolysis, and IFN-g production pathways. Clusters 3 and 10, which was upregulated by anti-PD-1 or anti-B7S1 but not by combinational blockade, were enriched with some pathways negatively regulate T cell function, such as execution of apoptosis, negative regulation of PI3K signaling, and IL-12 production, indicating that combinational blockade could overcome some negative effects caused by single blockades and preserve the long-lasting anti-tumor CD8 + T cells in the TME.
Taken together, multiple pathways exist to drive T cell exhaustion, providing basis for low response rates in cancer patients treated with anti-PD-1 therapy. Dual blockade of B7S1 and PD-1 pathways can synergistically reinvigorate anti-tumor CD8 + TILs, in part by acting on the same cells through shared downstream pathways. Moreover, combinatorial blockade also impacted additional pathways. Therefore, blockade of B7S1 pathway might help to improve the clinical efficacy of anti-PD-1 blockade in cancer therapy.
DISCUSSION
In summary, our results demonstrate that B7S1 is expressed by tumor-infiltrating APCs and drives dysfunction and exhaustion of activated CD8 + TILs via upregulating Eomes. B7S1 may be targeted together with PD-1 to further reverse T cell exhaustion and maximize the immunotherapeutic efficacy in cancer.
The majority of B7S1 expression was observed on CD45 + cells, especially professional APCs (macrophages and mDCs), in human and mouse HCC. However, E.G7 tumor cells displayed even higher B7S1 expression than APCs residing in the tumor of the E.G7 model. In addition, B7S1 expression was found on both tumor cells and APCs in patients with ovarian carcinoma (Kryczek et al., 2007) , which raises a question whether B7S1 on tumor cells or B7S1 on APCs is responsible for its immunosuppressive effects. We did not see further inhibition of tumor growth in Vtcn1 À/À mice when B7S1 on E.G7 tumor cells were blocked by anti-B7S1 Ab, consistent with the previous report that B7S1 expression on tumor-infiltrating macrophages, but not tumor B7S1, negatively correlates with patient outcome in patients with ovarian carcinoma (Kryczek et al., 2007) . Moreover, in vitro culture of OT-I with WT or Vtcn1 À/À APC further confirmed the inhibitory signals delivered from B7S1 on APCs to CD8 + T cells.
Thus, B7S1 on APC accounts for the immunosuppression of B7S1 in tumor, mainly through inhibiting the cross-presentation between professional APCs and CD8 + T cells.
Careful analysis of kinetic expression of the co-inhibitory molecules revealed induction of B7S1R at early stage on CD8 + TILs, while Tim-3 came up at later time points when B7S1R was reduced. Although B7S1 might promote T cell exhaustion via Eomes, PD-1 + B7S1R + Tim-3 À CD8 + TILs were actually activated instead of exhausted. Thus, it is likely that B7S1R drives T cell exhaustion of activated CD8 + TILs in the transition phase of activation-to-exhaustion. Studies of precise and detailed molecular pathways of B7S1 signaling in T cells require identification of B7S1R. One concern of targeting B7S1 for cancer immunotherapy is that the efficacy might be temporally limited to a specific window when B7S1R is expressed on CD8 + TILs. However, in cancer patients, neoantigens come up frequently because of genome instability and T cells against neoantigens get clonally expanded and travel to tumor tissues, in which they are induced to co-express PD-1 and B7S1R. Expression of B7S1R on CD8 + TILs was found not only in early-stage HCC patients, but also in late-stage HCC patients. In addition, even though expression of B7S1R decreased as a function of time in E.G7 tumor, there were still $20% B7S1R + CD8 + TILs at late stage in E.G7 tumor model. Therefore, efficacy of B7S1 blockade might be applicable to tumors at all stages.
Of note, Eomes, a paralog of T-bet, was previously known as a transcription factor critical for invoking cytotoxic effector differentiation of CD8 + T cells. Ectopic expression of Eomes is sufficient to endow attributes of CTL, including IFN-g, Perforin, and Granzyme B, to developing Th2 cells (Pearce et al., 2003) .
It also works redundantly with T-bet to regulate T cell-mediated anti-tumor immune responses . However, Eomes is upregulated in exhausted and terminally differentiated CD8 + T cells Wherry et al., 2007) . Our data also indicate that overexpression of Eomes in activated CD8 See also Figure S6 and Tables S4 and S5. T cells leads to impaired effector functions in response to T cell receptor (TCR) stimulation without CD28 co-stimulation in vitro and it is directly involved in regulation of T cell exhaustion by B7S1 signals. As previously reported, network analysis of CD8 + T cell memory versus exhaustion uncovers discrete coexpression neighbors of Eomes in the acute versus chronic network: the acute neighbors of Eomes are effector-biased genes and cell-cycle genes, while its chronic neighbors are genes involved in cytokine activity and CD8 + T differentiation (Doering et al., 2012) . Therefore, Eomes might have context-specific connectivity to distinct gene neighbors to induce cytotoxic effector differentiation and drive T cell exhaustion, in the effector and exhaustion phases, respectively. Moreover, reduction of Eomes binding was observed in CD8 + TILs when mice were treated with anti-B7S1 but not anti-PD-1, suggesting a unique regulation by B7S1 on Eomes in the cancer model.
Combination of PD-1 and B7S1 blockade showed synergic effects in eliciting strong anti-tumor responses in E.G7 and Hepa1-6 model. Unlike anti-PD-1 and anti-CTLA-4 which induce anti-tumor responses through distinct molecular mechanisms and differential engagement of specific T cell subsets (Wei et al., 2017) , anti-PD-1 and anti-B7S1 seemed to act on the same cell via many shared pathways, alluding to another kind of mechanism underlying synergistic effects of combinatorial blockade of immune checkpoints. Co-expression of B7S1R and PD-1 on CD8 + TILs and their largely overlapping downstream signaling might allow suppression of T cell induced by their ligands with different spatial and temporal distributions, e.g., B7S1 expressed on APCs and PD-L1 expressed on tumor cells in HCC patients. Moreover, when both pathways are on, inhibitory signals from each might work coordinately and generate ''1+1>2'' effects to further drive dysfunction and exhaustion of CD8 + TILs. Therefore, T cell exhaustion is determined by multiple co-inhibitory pathways and targeting the B7S1-B7S1R co-inhibitory pathway might enhance the efficacy of the current anti-PD-1 therapy for cancers, especially HCC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Mouse E.G7 tumor: Tumor tissues were embedded in O.T.C. and stored in À80 C. Sections were incubated in cold acetone for 10 min and washed 3 times with PBS. After blocking with 10% normal goat serum, each slide was incubated with fluorescence-conjugated antibodies against CD45.2 (104), B7S1 (188), CD34 (MEC 14.7), vimentin (280618) or control IgG for 1 hour at room temperature and then washed 3 times with PBS.
Slides were incubated with mounting medium with DAPI for 20 min. Images were obtained by a fluorescence microscope (Zeiss). The quantification analysis was performed by ImageJ software.
Ex vivo Cytolytic Assay
Cell suspension of spleen and tumor-infiltrating lymphocytes from WT and Vtcn1 À/À mice was stained with anti-CD8-V500 and anti-NK1.1-PercP-Cy5.5. CD8 + T cells and NK cells were sorted based on the staining. E.G7 was labeled with CFSE and pulsed with 3 mg/mL OVA257-264 at 37 C for 1 hour. Then 10 5 CD8 + T or NK were mixed with E.G7 at 1:1 ratio and incubated for 5h. Intracellular cleaved caspase 3-PE in CFSE + E.G7 was measured by flow cytometry.
Retroviral Expression and Adoptive Transfer
Eomes was cloned into a retroviral expression vector (RVKM) which also encodes an IRES-hCD2 cassette. This vector was transfected into Phoenix to package retrovirus. The empty vector was used as a control. CD8 + T cells were isolated from spleen and lymph nodes of OT-I mice using Dynabeads Flowcomp mouse CD8 kit (Invitrogen). Then the cells were stimulated with SIINFEKL peptide (OVA257-264) at 250 ng/mL in the presence of 10U/mL IL-2 for 24 hr. Retroviral supernatants were harvested, filtered, and supplemented with 6 mg/mL polybrene. OT-I T cell cultures were spinduced with the retroviral supernatant for 90 min at 1800 rpm, 32 C. 48 hr later, cells were sorted by hCD2 prior to re-stimulation or adoptive transfer. Overexpression of Eomes was confirmed by flow cytometry. hCD2 + OT-I cells were plated at 4 3 10 4 cells/well in 96-well plates and re-stimulated with 250ng/ml OVA, 2.5ng/mL OVA, 1 mg/mL coated anti-CD3 or 1 mg/mL coated anti-CD3 and anti-CD28 with 10U/mL IL-2 for 3 days. Golgi Plug was added 4 hours before harvesting the cells.
1.5 3 10 6 E.G7 was injected subcutaneously into 6$8-week-old female C57BL/6J mice. After 14 days, 0.5 3 10 6 hCD2 + OT-I cells was intravenously transferred into these mice. Rat IgG or anti-B7S1 (clone 54) was injected i.p. on Day 14, 16 and 18. Tumor growth was monitored every other day.
Co-culture of OT-1 and DC CD8 + T cells from spleens and lymph nodes of 6-12-week-old female OT-I mice were purified by Dynabeads Flowcomp mouse CD8 kit (Invitrogen). CD11c + DCs from spleen of WT and Vtcn1 À/À mice were labeled by anti-CD11c-PE antibody and isolated with anti-PE microbeads (Mitenyi Biotec) by magnetic cell separation. 10 5 OT-I cells and WT or Vtcn1 À/À DCs were cultured at 4:1 or 2:1 ratios supplied with 100 mg/mL OVA protein for 3 days. Golgi Plug was added 4 hours prior to flow cytometry analysis.
Expression of co-inhibitory receptors on adoptively transferred OT-I cells 10 6 E.G7 was subcutaneously inoculated in 6-8-week-old CD45.1 female mice. CD8+ T cells from spleens and lymph nodes of 6-12-week-old OT-I female mice (CD45.2 + ) were purified by Dynabeads Flowcomp mouse CD8 kit (Invitrogen) and labeled with CFSE. On Day 21, 5 3 10 6 OT-I cells were intravenously injected into E.G7-bearing mice. Mice were sacrificed for flow cytometry analysis of co-inhibitory receptors 1, 2 or 3 days after transfer.
RNA Processing
CD8
+ TILs were enriched using PE-conjugated anti-CD8a antibody and anti-PE microbeads. OVA-specific CD8 + TILs from E.G7-bearing WT and Vtcn1 À/À mice or mice treated with control Abs, anti-B7S1, anti-PD-1, anti-B7S1+anti-PD-1 (Day 21, 
Vtcn1
À/À mice (Day 21) were sorted into lysis buffer using BD FACSAria Cell Sorter. cDNA was made and library was constructed using SMARTer Ultra Low Input RNA for Illumina Sequencing-HV kit and Creator SMART cDNA Library Construction Kit (Clontech) according to manufacturer's instructions. The library products were sequenced via Illumina HiSeq2500 or Hiseq4000 by BerryGenomics or BGI Genomics. The sequencing reads were filtered by SOAPnuke without quality problems. Genome mapping was done by HISAT. Clean reads were mapped to the mm10 reference genome using Bowtie2, and gene expression indicated by RPKM (Reads Per Kilobases per Million reads) was calculated by RSEM. Differentially expressed genes (DEG) were detected with PoissonDis by at least 2 fold change and FDR lower than 0.001.
Epigenetic profiling by ATAC-seq OVA-specific CD8 + TILs from E.G7-bearing mice treated with control Abs, anti-B7S1, anti-PD-1, anti-B7S1+anti-PD-1 (Day 21, 6 mice per group) were isolated by enrichment of CD8 + T cells followed by FACS sorting. ATAC-seq DNA library was constructed using TruePrep DNA Library Prep Kit V2 for Illumina and TruePrep Index Kit V2 for Illumina. Briefly, 15,000$50,000 sorted cells were resuspended in 35 mL lysis buffer (10mM Tris-HCl, 10mM NaCl, 3mM MgCl 2 , 0.1% IGEPAL CA-630) and incubated on ice for 10 min with 3 times vortex. DNA fragmentation was conducted by adding 10 mL 5 3 TTBL, 5 mL TTE Mix and shaking at 37 C for 30 min. Fragmented DNA was purified using 1.8 3 AMPure beads, barcoded with dual indexes and PCR amplified. Size selection and purification of DNA fragments were done using AMPure beads. Size distribution and molarity of the sequencing library were determined by Qubit (Thermo Fisher Scientific). Sequencing was performed using Illumina X-ten by Novogene. Paired-end reads were mapped to the mm10 reference genome using Bowtie2. Only concordantly mapped pairs were kept for further analysis. Peak calling was performed using MACS2 to identify areas of sequence tag enrichment. BedTools was used to find common intersection between identified peaks (1bp minimum overlap) and to create a merged peak list. mmTF motif analysis was computed using HOMER (homer.salk.edu).
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq Analysis
To generate gene-sets for GSEA, we identified DEGs between effector (Day 15 p.i.) and exhausted (Day 30 p.i.) CD8 + T cells in LCMV (clone 13) infection from GSE41867 (FDR < 0.05 and fold changeR2). We identified DEGs between activated (4 days after infection with adenovirus AdPIAt) and exhausted (TiRP autochthonous melanoma) CD8 + T cells from GSE42824. The effector gene list was from (Pauken et al., 2016) . All these selected genes were constituted as gene sets for the subsequent GSEA analysis (https://www.broadinstitute.org/gsea) (Subramanian et al., 2005 . Enrichment analysis for each cluster with MSigDB gene sets (Subramanian et al., 2005) or gene signatures generated from the literatures was computed as the hypergeometric p value for the overlap between the cluster and the gene set of interest. For LCMV exhaustion and memory signature, we compiled the gene-sets from GSE9650 on MSigDB identified as upregulated in exhausted and memory CD8 + T cells when compared to other status, respectively. For TIL exhaustion signature, we selected genes upregulated in TILN of melanoma patients (mean fold change R 2, p value corrected by FDR < 0.05) in comparison with naive CD8 + T from PBMC (GEO: GSE24536) (Baitsch et al., 2011) . For activation signature, we identified genes highly expressed in activated (4 days after infection with adenovirus AdPIAt) CD8
+ T compared to naive and exhausted (TiRP autochthonous melanoma) CD8 + T cells from GSE42824 (logFC R 6, p value corrected by FDR < 0.05) (Giordano et al., 2015) .
Statistical analysis
Statistical comparisons were performed using ordinary One-way ANOVA analysis followed by multiple comparisons or non-parametric Mann-Whitney test. Statistical analysis of tumor growth curves was performed using linear regression. P values less than 0.05 were considered to be statistically significant.
DATA AND SOFTWARE AVAILABILITY
Gene Expression Omnibus: RNA-seq data have been deposited under accession code GSE110249; ATAC-seq data is available under accession number GSE110251.
